{
  "trial_id": "NCT03977610",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Males with 40-85 years of age and life expectancy more than 3 months",
      "label": "met"
    },
    {
      "criterion": "Pathology-proved prostate cancer patients and classified as clinical stage III or IV (including lymph node or bone metastasis)",
      "label": "met"
    },
    {
      "criterion": "Willing to sign the informed consent",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Unable to tolerate the PET/CT scan, such as those with claustrophobia, unable to lie still, consciousness unclear, vital sign unstable.",
      "label": "triggers"
    },
    {
      "criterion": "With renal impairment (glomerular filtration rate lower than 30 ml/min/1.73 m2), and allergy to medium contrast.",
      "label": "triggers"
    }
  ],
  "notes": "",
  "_meta": {
    "topic_id": "45",
    "trial_id": "NCT03977610",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}